Doc,
I even complimented one of your posts and ask others to give you a break, as insightful debate on here serves purpose for us all. But how about just letting it go now. The cases were anecdotal evidence at best. The vast majority of us get that (ignore the others). But on the flip-side you didn't really discuss the anecdotal evidence in a very objective approach, hence all this started.
If you have something specifically insightful to say, negative or positive to MSB, go for it, but this thread is becoming you vs everyone else. Now I am a bit prone to a bit of frustrated shouting at clouds myself, but there's a time to let go.
On a slightly more constructive note to this thread and pertinent to it, the very respectable Lancet has published a related article on a similar syndrome (MIS-A) in adults
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00085-0/fulltext
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-369
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |